ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: jaybe	2/3/2016 10:27:00 PM
	of 4474

Mayo Clinic uses AP20187 to help extend lifespan of mice... Actually a trans-gene was used to inhibit (clear) p16ink4a, but AP20187 was the facilitator (dimerizer), similar to Bellicum's use of AP1903 as a safety switch for CAR-T cells, however, in this case the trans-gene is turned on by the dimer. "We show that compared to vehicle alone, AP20187 treatment extended median lifespan in both male and female mice of two distinct genetic backgrounds." Not sure if this is meaningful, could yield additional licensing fees. Hard to follow the patent trail on AP20187 as it extends back to 1997 with several continuation filings, adding new methods and compounds, most recent priority date is 2011. Additional methods for synthesizing '187 were filed in 2012. nature.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next